6/29/23, 11:57 PM Solidarity (remdesivir) Pathway Feedback Search Clinical Topics Home Studies Solidarity (remdesivir) Solidarity (remdesivir) Disease COVID 19 infection Trial question What is the role of remdesivir in patients hospitalized with COVID-19? Study design Multi-center Open label RCT Population Characteristics of study participants 37.0% female N = 8275 63.0% male 8275 patients (3035 female, 5240 male) Inclusion criteria: adult patients hospitalized with COVID-19 Key exclusion criteria: serious chronic liver; heart disease; pregnancy Interventions N=4146 remdesivir (10 daily infusions unless discharged earlier) N=4129 no remdesivir (standard of care alone) Primary outcome In-hospital mortality 15.6 % 15.6 14.5 https://web.pathway.md/studies/recRqmfTo4ZnEUlbY 1/2 6/29/23, 11:57 PM Solidarity (remdesivir) Pathway 11.7 % 7.8 % 3.9 % No significant difference 0.0 % Remdesivir No remdesivir No significant difference in in-hospital mortality (14.5% vs. 15.6%; RR 0.91, 95% CI 0.82 to 1.02) Secondary outcomes Significant decrease in progression to ventilation (14.1% vs. 15.7%; RR 0.88, 95% CI 0.77 to 1) Significant decrease in death or progression to ventilation (19.6% vs. 22.5%; RR 0.84, 95% CI 0.75 to 0.93) Conclusion In adult patients hospitalized with COVID-19, remdesivir was not superior to no remdesivir with respect to a in-hospital mortality. Reference WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet. 2022 May 21;399(10339):1941-1953. Open reference URL https://web.pathway.md/studies/recRqmfTo4ZnEUlbY 2/2